Pharma News
07 Jan 2024 to 13 Jan 2024
Jan 11, 2024
European Commission Approves Pfizer's Latest Development
Pfizer's TALZENNA (talazoparib) has received approval from the European Commission (EC) for its use in combination with XTANDI (enzalutamide) as a treatment for metastatic castration-resistant prostate cancer (mCRPC) in adult patients. This makes TALZENNA the first and only PARP inhibitor licensed in the European Union for use with XTANDI in mCRPC patients, regardless of gene mutations, offering new hope to those in the most advanced stage of the disease.
